About Phthisis Diagnostics
Phthisis Diagnostics is a Healthcare company based in Charlottesville (United States) founded in 2005, and was acquired by Microbiologics in October 2013. It operates as a molecular standards for infectious disease diagnostics are designed and manufactured. Phthisis Diagnostics has raised $1.15 million across 7 funding rounds from investors including HHS, Afton Scientific and Microbiologics. Its focus areas include Life Sciences, Genomics, Applied Genomics and Microbial Genomics. Its competitors include Sino Biological, GenScript, Miltenyi Biotec, Manus Bio and Devyser and 3 more; 5 of its 8 listed competitors have raised funding.
Company details
Phthisis Diagnostics is now the molecular products division at Microbiologics. They have a patented process for designing and manufacturing molecular standards. These molecular standards are specifically designed to be used as performance controls for a wide variety of molecular instruments and assays in the pharmaceutical, food safety, and clinical testing. Helix Elite Molecular Standards are specifically designed and synthetically produced nucleic acids for use as a genetic surrogate for pathogens that are difficult to grow or that require specialized facilities or staff. Each standard contains consensus sequences of diagnostic regions from the targets genome and represents the known genetic diversity of the microorganism.
- Headquarters Charlottesville, United States
- Stage Acquired
- SectorsHealthcare
- Website phthisisdiagnostics.com
- Social LinkedIn X
- Acquired by Microbiologics (Oct 2013)
- Total Equity Funding$1.15M (USD)
in 7 rounds
- Latest Funding Round$410K (USD), Series A
Jul 2012
- InvestorsHHS
& 9 more
- Acquired byMicrobiologics
(Oct 2013)
Funding Insights of Phthisis Diagnostics
Phthisis Diagnostics has successfully raised a total of $1.15M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $410 thousand completed in July 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.15M
- Total Rounds 7
- Last Round Series A — $410,000
- First Round $958,924
(Aug 2008)
- Investors Count 9
All 7 funding rounds of Phthisis Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2012 | $410,000 | Series A | – | Piedmont Angel Network | |
| Apr 2012 | $285,000 | Series A | – | – | – |
| Apr 2011 | $450,000 | Series A | – | – | – |
| Feb 2010 | $153,916 | Grant | – | – | |
| Jan 2010 | $101,684 | Grant | – | – | |
| Jul 2009 | $958,924 | Grant | – | – | |
| Aug 2008 | $958,924 | Grant | – | – |
10 investors in total: 10 institutional.
Investors in Phthisis Diagnostics
Phthisis Diagnostics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Afton Scientific and Microbiologics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are provided to Mid-Atlantic startups by this group. | – | newdominionangels.com | - | |
Angel Network | 2001 | piedmontangelnetwork.com | Winston-salem, United States | |
Family owned investment firm | – | moodooslp.com | San Diego, United States | |
Diversified investment management services are provided to clients. | 2000 | piedmontinvestmentadvisors.com | Durham, United States | |
- | – | virgaventures.com | - | |
Company offering aseptic filling services and sterile vials | 2000 | aftonscientific.com | Charlottesville, United States | |
Economic development is driven through technology innovation and commercialization. | – | virginiaipc.org | Richmond, United States | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Lyophilized quality control microorganisms are supplied for diverse industries. | 1971 | microbiologics.com | Saint Cloud, United States |
Investor details for Phthisis Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Phthisis Diagnostics
4 dated milestones of Phthisis Diagnostics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Phthisis Diagnostics is founded.
- Funding First funding round of $959K.
- Funding Latest funding round, Series A, of $410K.
- Exit Acquired by Microbiologics.
Competitors of Phthisis Diagnostics
Phthisis Diagnostics has 8 listed competitors in our database, 5 of them funded. They include Sino Biological, GenScript, Miltenyi Biotec, Manus Bio and Devyser, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| manusbio.com | 2011 | Cambridge, United States | $115.93M | – | Phytochemicals are developed using microbial fermentation processes. | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| kallyope.com | 2014 | New York, United States | $479M | 84 | The gut-brain axis is explored for therapeutic and nutritional innovations. | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| sebia.com | 1967 | Evry Courcouronnes, France | – | – | Electrophoresis-based in vitro diagnostics products are developed and provided. |
Detailed competitors of Phthisis Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Phthisis Diagnostics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Phthisis Diagnostics
Phthisis Diagnostics was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Phthisis Diagnostics is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Phthisis Diagnostics is a funded company, having raised a total of $1.15M across 7 funding rounds to date. The company's 1st funding round was a Grant of $958.92K, raised on Aug 2008.
Phthisis Diagnostics is now the molecular products division at Microbiologics. They have a patented process for designing and manufacturing molecular standards. These molecular standards are specifically designed to be used as performance controls for a wide variety of molecular instruments and assays in the pharmaceutical, food safety, and clinical testing. Helix Elite Molecular Standards are specifically designed and synthetically produced nucleic acids for use as a genetic surrogate for pathogens that are difficult to grow or that require specialized facilities or staff. Each standard contains consensus sequences of diagnostic regions from the targets genome and represents the known genetic diversity of the microorganism.
Phthisis Diagnostics's top competitors include Sino Biological, Manus Bio and Kallyope.
Phthisis Diagnostics has 10 investors. Key investors include HHS, Afton Scientific, Microbiologics, Piedmont Investment Advisors, and Piedmont Angel Network.
Yes. Phthisis Diagnostics was acquired by Microbiologics in October 2013.